Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a
chromosome translocation that generates the Bcr-Abl oncogene encoding a constitutive …

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder characterized by
the presence of a fusion oncogene BCR‐ABL, which encodes a protein with constitutive TK …

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …

Chronic myeloid leukemia (CML) is typified by robust marrow and extramedullary myeloid
cell production. In the absence of therapy or sometimes despite it, CML has a propensity to …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Although rare, chronic myeloid leukemia (CML) represents an important paradigm for
understanding the molecular events leading to malignant transformation of primitive …

Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to
kinase inhibitors and responsible for minimal residual disease in treated patients. We …

Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph+)
chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease …